Written By Betty van der Mark on Wednesday, September 1, 2010 | 7:59 AM
Victoza has been on the market in Europe since last year. It's used to treat the early stages of type 2. Victoza has been so successful in reducing patients' weight that the company Novo Nordisk is considering testing whether Victoza could be used to treat severe obesity – a condition often associated with diabetes. Novo is now deciding how to run final-stage trials to test whether Victoza could be used to treat obesity and using the drug for this application could still be five years away. But if successful, it could signal a move by Novo into prevention of diabetes as well as the treatment of a condition which currently affects about 285m people and is expected to affect 483m people by 2030.